Preclinical experiments conducted in canine brain cancer models have shown that these EGFR-targeted vehicles loaded with doxorubicin exhibited highly significant tumor regression ( 54 ).
1
—
—
Preclinical experiments conducted in canine brain cancer models have shown that these EGFR-targeted vehicles loaded with doxorubicin exhibited highly significant tumor regression ( 54 ).